Sensus Healthcare (SRTS) Set to Release Earnings on Thursday

Posted by Brian Himes on Nov 10th, 2026

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) is projected to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Sensus Healthcare to post earnings of ($0.0550) per share and revenue of $6.61 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million.

Sensus Healthcare Stock Performance

SRTS opened at $3.18 on Tuesday. The stock’s 50 day moving average price is $3.00 and its 200 day moving average price is $3.49. Sensus Healthcare has a 12 month low of $2.66 and a 12 month high of $5.49.

Analyst Upgrades and Downgrades

SRTS has been the topic of a number of research analyst reports. Lake Street Capital lowered their price target on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $5.83.

Check Out Our Latest Stock Report on Sensus Healthcare

Insiders Place Their Bets

In related news, Director Eric Sachetta acquired 37,537 shares of the company’s stock in a transaction on Friday, August 28th. The shares were purchased at an average price of $3.44 per share, for a total transaction of $129,127.28. Following the purchase, the director owned 267,480 shares in the company, valued at $920,131.20. This represents a 16.32% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 120,171 shares of company stock worth $405,230 over the last quarter. 10.20% of the stock is currently owned by insiders.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin.

Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.

Founded in 2010, Sensus Healthcare is headquartered in Boca Raton, Florida.